Search

Denis Y Drygin

age ~51

from San Diego, CA

Get Report
Also known as:
  • Dennis Y Drygin
  • Denis N
Related to:
Connected to:

Denis Drygin Phones & Addresses

  • San Diego, CA
  • Vista, CA
  • 1040 N Pleasant St, Amherst, MA 01002 • 4135494436
  • Belchertown, MA
  • 1040 N Pleasant St, Amherst, MA 01002 • 4133299831

Work

  • Company:
    Cylene pharmaceuticals
    Jan 2012
  • Position:
    Vice president, biology

Education

  • Degree:
    Ph.D
  • School / High School:
    University of Massachusetts, Amherst
    1999 to 2002
  • Specialities:
    Biochemistry, Molecular & Cellular Biology

Skills

Drug Discovery • Life Sciences • Cell Based Assays • In Vivo • Biotechnology • In Vitro • Molecular Biology • Cell Biology • Cancer • Biochemistry • Pharmacology • Research • R&D • Assay Development • Lifesciences • Cell • Protein Chemistry • Oncology • Chemistry • Clinical Development • Cro • Pharmacokinetics • Pharmaceutical Industry • Translational Medicine • Ind • Toxicology • Clinical Trials • Translational Research • Drug Development • Biomarker Discovery • Cell Signaling • Medicinal Chemistry • Small Molecules • Biomarkers • Cro Management • Research and Development

Languages

English • Russian

Industries

Pharmaceuticals

Us Patents

  • Methods For Treating Aberrant Cell Proliferation Disorders

    view source
  • US Patent:
    20080318938, Dec 25, 2008
  • Filed:
    Jun 20, 2008
  • Appl. No.:
    12/143223
  • Inventors:
    David M. RYCKMAN - San Diego CA, US
    Denis Drygin - San Diego CA, US
    Jeffrey P. Whitten - Santee CA, US
    Kenna Anderes - San Diego CA, US
    Katy Trent - San Diego CA, US
    Levan Darjania - Escondido CA, US
    Mustapha Haddach - San Diego CA, US
    Sean O'Brien - Carlsbad CA, US
    William G. Rice - Del Mar CA, US
  • International Classification:
    A61K 31/5383
    A61P 35/02
    A61P 35/00
  • US Classification:
    5142295
  • Abstract:
    The invention relates in part to methods for inhibiting proliferation of cancer cells and treating one or more cell proliferative conditions using compounds described herein.

  • Human Ribosomal Dna (Rdna) And Ribosomal Rna (Rrna) Nucleic Acids And Uses Thereof

    view source
  • US Patent:
    20090181377, Jul 16, 2009
  • Filed:
    Feb 4, 2008
  • Appl. No.:
    12/025705
  • Inventors:
    Denis Drygin - San Diego CA, US
    Emil Michelotti - Foster City CA, US
    Sean O'Brien - Carlsbad CA, US
    William G. Rice - Del Mar CA, US
    Jeffrey P. Whitten - Santee CA, US
  • Assignee:
    Cylene Pharmaceuticals, Inc. - San Diego CA
  • International Classification:
    C12Q 1/68
    C07H 21/02
  • US Classification:
    435 6, 536 231
  • Abstract:
    Provided herein are isolated nucleic acids that comprise a human rRNA or rDNA subsequence and related compositions and methods of use.

  • Treatment Of Neoplastic Disorders Using Combination Therapies

    view source
  • US Patent:
    20100173013, Jul 8, 2010
  • Filed:
    Jan 7, 2010
  • Appl. No.:
    12/684053
  • Inventors:
    Denis Drygin - San Diego CA, US
    Kenna Anderes - San Diego CA, US
    Caroline B. Ho - Valley Center CA, US
    Joshua R. Bliesath - Escondido CA, US
    Christopher B. Proffitt - Poway CA, US
    Sean O'Brien - Carlsbad CA, US
    William G. Rice - Del Mar CA, US
  • International Classification:
    A61K 31/4375
    A61K 31/519
    A61K 33/24
    A61K 31/675
    A61K 31/5377
    A61P 35/00
    A61P 37/06
    A61K 31/704
    A61K 31/7076
    A61K 31/7068
    A61K 31/517
    A61K 31/437
  • US Classification:
    424649, 514267, 514292, 514 81, 5142335, 514 34, 514 48, 514 49, 51426624, 514283
  • Abstract:
    The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders.

  • Biomarkers For Predicting The Sensitivity And Response Of Protein Kinase Ck2-Mediated Diseases To Ck2 Inhibitors

    view source
  • US Patent:
    20110212845, Sep 1, 2011
  • Filed:
    Oct 4, 2010
  • Appl. No.:
    12/897640
  • Inventors:
    Denis DRYGIN - San Diego CA, US
    Sean E. O'BRIEN - Carlsbad CA, US
    Kenna L. ANDERES - San Diego CA, US
    Daniel VON HOFF - Scottsdale AZ, US
    John K.C. LIM - San Diego CA, US
    Claire S. PADGETT - San Diego CA, US
    Joshua R. BLIESATH - Escondido CA, US
    Caroline B. HO - Valley Center CA, US
    William G. Rice - San Diego CA, US
  • International Classification:
    C40B 30/00
    C12Q 1/48
    C12Q 1/02
    C12Q 1/68
    G01N 33/53
  • US Classification:
    506 7, 435 15, 435 29, 435 613, 435 792
  • Abstract:
    Disclosed are biomarkers for determining the sensitivity of protein kinase CK2-mediated diseases, such as proliferative and/or inflammatory disorders, to treatment with CK2 inhibitors. These biomarkers can be used to predict or select subjects likely to be responsive to treatment with a CK2 inhibitor, and to treat or monitor subjects undergoing treatment with a CK2 inhibitor.

  • Human Ribosomal Dna (Rdna) And Ribosomal Rna (Rrna) Nucleic Acids And Uses Thereof

    view source
  • US Patent:
    20070117770, May 24, 2007
  • Filed:
    Aug 18, 2006
  • Appl. No.:
    11/506588
  • Inventors:
    Denis Drygin - San Diego CA, US
    Emil Michelotti - San Diego CA, US
    Sean O'Brien - Carlsbad CA, US
    William Rice - Del Mar CA, US
    Jeffrey Whitten - Santee CA, US
  • Assignee:
    Cylene Pharmaceuticals, Inc. - San Diego CA
  • International Classification:
    A61K 48/00
    A61K 31/496
    A61K 31/4709
    C07H 21/04
  • US Classification:
    514044000, 514253080, 514312000, 536023200
  • Abstract:
    Provided herein are isolated nucleic acids that comprise a human rRNA or rDNA subsequence and related compositions and methods of use.

Resumes

Denis Drygin Photo 1

Chief Scientific Officer

view source
Location:
14125 Via Alisal, San Diego, CA 92128
Industry:
Pharmaceuticals
Work:
Cylene Pharmaceuticals since Jan 2012
Vice President, Biology
Cylene Pharmaceuticals May 2011 - Dec 2011
Executive Director, Biology
Cylene Pharmaceuticals Jul 2007 - May 2011
Director, Biology
Cylene Pharmaceuticals Oct 2005 - Jul 2007
Scientist II, Drug Mechanism Lab
Cylene Pharmaceuticals May 2005 - Oct 2005
Research Scientist I, Drug Mechanism Lab
Education:
University of Massachusetts, Amherst 1999 - 2002
Ph.D, Biochemistry, Molecular & Cellular Biology University of Massachusetts, Amherst 1995 - 1999
M.S, Biochemistry, Molecular & Cellular Biology Московский Государственный Университет им. М.В. Ломоносова (МГУ) / Lomonosov Moscow State University (MSU) 1994 - 1995
M.S, Chemistry Московский Государственный Университет им. М.В. Ломоносова (МГУ) / Lomonosov Moscow State University (MSU) 1990 - 1994
B.S, Chemistry
Skills:
Drug Discovery
Life Sciences
Cell Based Assays
In Vivo
Biotechnology
In Vitro
Molecular Biology
Cell Biology
Cancer
Biochemistry
Pharmacology
Research
R&D
Assay Development
Lifesciences
Cell
Protein Chemistry
Oncology
Chemistry
Clinical Development
Cro
Pharmacokinetics
Pharmaceutical Industry
Translational Medicine
Ind
Toxicology
Clinical Trials
Translational Research
Drug Development
Biomarker Discovery
Cell Signaling
Medicinal Chemistry
Small Molecules
Biomarkers
Cro Management
Research and Development
Languages:
English
Russian
Get Report for Denis Y Drygin from San Diego, CA, age ~51
Control profile